RM-END / Endocrine and peptide-hormone analogs
Lanreotide
Also known as: Somatuline Depot · Lanreotide acetate · BIM 23014
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. The labeled comparator is a specific supersaturated prolonged-release acetate formulation.
Evidence position
The regulated product and human evidence support Grade A for the defined finished presentation.
What the record does not establish
Evidence for the labeled syringe does not authenticate loose peptide or make a different formulation equivalent.
Sources
- 01Lanreotide compound recordPubChem
- Shows
- Registry identity, structure, formula and synonyms for lanreotide
- Does not show
- Does not establish a finished-product formulation or lot-specific quality
- 02Somatuline Depot prescribing informationDailyMed / U.S. National Library of Medicine
- Shows
- Current U.S. label, peptide identity and prolonged-release formulation
- Does not show
- Does not qualify loose lanreotide, another salt or another delivery system
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Lanreotide
- CID
- 6918011
- Formula
- C54H69N11O10S2
- Mass
- 1096.3
PUBMED / FOUND RECORDS
- Lanreotide in metastatic enteropancreatic neuroendocrine tumors.The New England journal of medicine / 2014 Jul 17PMID 25014687 / DOI 10.1056/NEJMoa1316158
- Lanreotide. / 2012PMID 31643689
- Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.Endocrine / 2021 FebPMID 33052555 / DOI 10.1007/s12020-020-02475-2
- Lanreotide. / 2006PMID 31145576
- Carcinoid Syndrome. / 2026 JanPMID 28846309
CLINICALTRIALS.GOV / FOUND RECORDS
- Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic PatientsCOMPLETED / PHASE3 / IpsenNCT00210457 / DIRECT intervention MATCH: Lanreotide
- LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)ACTIVE_NOT_RECRUITING / PHASE2 / Antonio FojoNCT03946527 / DIRECT intervention MATCH: Lanreotide
- Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.COMPLETED / NO PHASE / IpsenNCT02396966 / DIRECT title MATCH: Lanreotide
- Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid SyndromeWITHDRAWN / PHASE3 / European Organisation for Research and Treatment of Cancer - EORTCNCT04065165 / DIRECT intervention MATCH: Lanreotide
- Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal ObstructionCOMPLETED / PHASE2 / IpsenNCT02275338 / DIRECT intervention MATCH: Lanreotide